A part of a global business group based in UK with investments in science, research and education, Mumbai based pharma company ‘Elbrit Life Sciences’ announced the commencement of its operations to target cardiac and diabetes product segments in the present year. As a part of its plan, the company will be serving patients across South India in the initial phase and aims to cover the entire country in the near future.
The group has significantly invested in the next generation healthcare such as genetic therapy, molecular biology, DNA mapping and biomarkers. The group also owns world renowned scientific and academic publishing brands.
Says Prakash, chief executive officer, Elbrit Life Sciences, “We are extremely excited to announce the launch of Elbrit Life Science. We will be initially venturing into branded generics in diabetes and cardiac segments. In the near future, we will be adding more innovative and super speciality products to our portfolio. Our goal is to expand into other pharmaceutical segments as well and become a leading player in the market in the time to come.”
The company is aggressively planning to pursue the Indian pharmaceutical space. If experts in the field are to be believed, the launch of ‘Elbrit Life Sciences’ is likely to change the Indian pharmaceutical sector on its head resulting in better quality and healthy competition. With the major Indian pharmaceutical companies facing tough times over quality issues in the US and Europe, healthy competition in the domestic market is an encouraging sign for patients.